The Top 5 Biosimilars Articles for the Week of February 3

Article

The Center for Biosimilars® recaps the top stories for the week of February 3, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 3, 2020.

Number 5: The European Medicines Agency’s Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer's Ruxience, a rituximab biosimilar.

Number 4: The FDA announces 6 final guidance documents on gene therapy manufacturing and clinical development of products, as well as a draft guidance regarding gene therapies and orphan drugs.

Number 3: In an effort to speed more generic drug approvals, the FDA says it is changing how it assigns priority review status to abbreviated new drug applications.

Number 2: Celltrion recalls its employees from China’s Wuhan province until the coronavirus outbreak is brought under control.

Number 1: Merck says it is spinning off its biosimilars business to focus on its oncology drug Keytruda.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
The Top 5 Biosimilar Articles for the Week of February 19, 2024.
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
The top 5 biosimilar articles for the week of February 5, 2024.
The Top 5 Biosimilar Articles for the Week of January 29
Here are the top 5 biosimilar articles for the week of January 15, 2024.
The Top 5 Center for Biosimilars Articles for the Week of January 8, 2024.
Prerakkumar Parikh, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.